前列腺素衍生物拉坦前列素(适利达)与噻吗心安治疗青光眼的临床对比研究

目的 :验证前列腺素衍生物拉坦前列素 (适利达 )治疗青光眼的临床疗效和安全性。方法 :采用双盲、随机对照的方法 ,对46例原发性开角型青光眼和高眼压症患者进行为期12周的研究 ,观察其降眼压疗效和不良反应。用0 005 %拉坦前列素每日滴眼1次与0 5 %噻吗心安每日滴眼2次进行随机对比。治疗前 ,治疗后2周、6周及12周随访 ,测量眼压并观察眼局部及全身不良反应。结果 :在入选的46例患者中 (拉坦前列素组22例 ,噻吗心安组24例 ) ,拉坦前列素组平均眼压下降值为 (7 86±2 39)mmHg(下降31 1 % ,P<0 001) ;噻吗心安组为 (6 24±2 58)mmHg(下降24 9 % ,P<0 001)。两组之差1 62mmHg(P<0 01)。拉坦前列素组2例有眼部异物感及充血 ,未发现其他与药物有关的眼部和全身不良反应。结论 :拉坦前列素的降眼压疗效优于噻吗心安 ,且无明显毒、副作用 ,1天仅用1次 ,是理想的抗青光眼药物。

A Comparative Study of Latanoprost and Timolol in Treating Patients With Glaucoma or Ocular Hypertension

OBJECTIVE： To confirm the efficacy and safety of latanoprost in treating glaucoma.METHODS： In a double blind， randomized control clinical trial， we compared the efficacy and adverse drug reactions of once daily topically applied 0.005％ latanoprost with those of twice daily 0.5％ timolol for 12 weeks in patients with open angle glaucoma or ocular hypertension.RESULTS： The study included 46 patients（22 pts.randomized to latanoprost treatment， 24 pts.to timolol） ， 46 patients remained at the end of the study.Comparing with baseline diurnal intraocular pressure（IOP） ， the IOP reduction（mean±standard deviation） achieved with latanoprost（7.86±2.39） mmHg， （31.1％， P<0.001），and timolol（6.24±2.58）mmHg （24.9%，P<0.001），the difference between the two groups（1.62mmHg） being significant（P<0.01）. Two patients treated with latanoprost had foreign body sensation. No other ocular and systemic adverse reactions related to the two drugs were found. CONCLUSION: The results of this study demonstrated that 0.005% latanoprost applied once daily is well tolerated and more effective in reducing IOP than 0.5% timolol applied twice daily. Thus, latanoprost has the potential for becoming one of the ideal antiglaucoma drugs.